Key facts: Sanofi acquires Vigil Neuroscience for $470 million; Formycon shares rise 8%
I'm PortAI, I can summarize articles.
Sanofi acquired Vigil Neuroscience for $470 million, with a potential $600 million contingent payment, to develop a first-in-class TREM2 agonist for Alzheimer's disease.1Shares in Formycon rose around 8% following the announcement of its FYB208 drug as a biosimilar candidate for Dupixent, which is produced by Regeneron Pharmaceuticals in partnership with Sanofi.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments